Keyword: Novan Therapeutics
The appointment puts the former FDA commissioner in a position to work with Immunocore, Poseida Therapeutics and the fund's other cancer biotechs.
Investors who bought into Novan Therapeutics' cut-price public listing last year have seen the company's share price halve since then—but look set to recoup some of those losses after the company reported a positive phase 2 trial.
Nitric oxide dermatology player Novan nabbed a nice share price pop on its first day of trading; after the first few hours it had gained 55%.
In a year when many smaller biotechs have had to ditch their public offerings entirely, Novan may count itself lucky it can go for an IPO at all, despite having to settle for a lower amount.